Home › Companies › Allogene Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Allogene Therapeutics, Inc.’s Form 8-K, filed June 22, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2026: 6 items on Allogene Therapeutics, Inc.’s Form 8-K, filed June 22, 2026: 3 elected · 3 approved.
Notable dissent: 3 directors (17.1%, 11.4%, 11.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Allogene Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Allogene Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Deborah Messemer | 202,325,767 | -- | -- | 26,099,641 | 54,299,010 | 89% | Elected | — |
| Elect Director: Vicki Sato, Ph.D. | 202,326,299 | -- | -- | 26,099,109 | 54,299,010 | 89% | Elected | — |
| Elect Director: Owen Witte, M.D. | 189,310,484 | -- | -- | 39,114,924 | 54,299,010 | 83% | Elected | — |
| 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers | 213,098,167 | 11,951,256 | 3,375,985 | -- | 54,299,010 | 95% | Approved | — |
| 4. Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares | 221,767,995 | 6,535,254 | 122,159 | -- | 54,299,010 | 97% | Approved | — |
| 5. Ratification of the Selection of Independent Registered Public Accounting Firm | 282,022,884 | 503,156 | 198,378 | -- | 0 | 99.8% | Approved | — |
Source: Allogene Therapeutics, Inc., Form 8-K, filed with the SEC on June 22, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
181 asset managers disclosed a vote on at least one Allogene Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Allogene Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Deborah Messemer
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Deborah Messemer”): 202,325,767 for, 26,099,641 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 62,586,527 for, 2,207,797 withheld, 98 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,783,583 | 0 | 98 | 23,667 | For |
| Fidelity | 12,491,517 | 0 | 0 | 0 | For |
| BlackRock | 8,024,301 | 0 | 0 | 0 | For |
| State Street | 5,360,206 | 0 | 0 | 13,091 | For |
| T. Rowe Price | 3,707,029 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,375,270 | 0 | 0 | 0 | For |
| TIAA | 2,421,840 | 0 | 0 | 0 | For |
| Charles Schwab | 1,871,494 | 0 | 0 | 0 | For |
| Invesco | 591,457 | 0 | 0 | 0 | For |
| Equitable | 331,345 | 0 | 0 | 165,041 | Mixed |
| Nationwide | 47,412 | 0 | 0 | 318,050 | Mixed |
| JPMorgan | 306,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 250,000 | Withhold |
| Columbia Threadneedle | 244,527 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 237,500 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 172,026 | Withhold |
| John Hancock | 125,876 | 0 | 0 | 40,876 | Mixed |
| GuideStone | 0 | 0 | 0 | 166,200 | Withhold |
| ProShares | 0 | 0 | 0 | 154,377 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 140,772 | Withhold |
| Brighthouse | 81,804 | 0 | 0 | 50,340 | Mixed |
| Dimensional | 0 | 0 | 0 | 113,711 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 113,627 | Withhold |
| Lincoln Financial | 93,800 | 0 | 0 | 17,215 | Mixed |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Owen Witte, M.D.
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Owen Witte, M.D.”): 189,310,484 for, 39,114,924 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 53,952,168 for, 10,842,112 withheld, 142 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,771,852 | 0 | 142 | 35,353 | For |
| Fidelity | 9,446,272 | 0 | 0 | 3,045,245 | Mixed |
| BlackRock | 8,024,301 | 0 | 0 | 0 | For |
| State Street | 3,863 | 0 | 0 | 5,369,434 | Withhold |
| T. Rowe Price | 3,707,029 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,375,270 | 0 | 0 | 0 | For |
| TIAA | 2,421,840 | 0 | 0 | 0 | For |
| Charles Schwab | 1,871,494 | 0 | 0 | 0 | For |
| Invesco | 591,457 | 0 | 0 | 0 | For |
| Equitable | 331,345 | 0 | 0 | 165,041 | Mixed |
| Nationwide | 47,412 | 0 | 0 | 318,050 | Mixed |
| JPMorgan | 306,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 250,000 | Withhold |
| Columbia Threadneedle | 244,527 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 237,500 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 172,026 | Withhold |
| John Hancock | 125,876 | 0 | 0 | 40,876 | Mixed |
| GuideStone | 0 | 0 | 0 | 166,200 | Withhold |
| ProShares | 0 | 0 | 0 | 154,377 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 140,772 | Withhold |
| Brighthouse | 81,804 | 0 | 0 | 50,340 | Mixed |
| Dimensional | 0 | 0 | 0 | 113,711 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 113,627 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 111,015 | Withhold |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Vicki Sato, Ph.D.
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Vicki Sato, Ph.D.”): 202,326,299 for, 26,099,109 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 62,586,527 for, 2,207,797 withheld, 98 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,783,583 | 0 | 98 | 23,667 | For |
| Fidelity | 12,491,517 | 0 | 0 | 0 | For |
| BlackRock | 8,024,301 | 0 | 0 | 0 | For |
| State Street | 5,360,206 | 0 | 0 | 13,091 | For |
| T. Rowe Price | 3,707,029 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,375,270 | 0 | 0 | 0 | For |
| TIAA | 2,421,840 | 0 | 0 | 0 | For |
| Charles Schwab | 1,871,494 | 0 | 0 | 0 | For |
| Invesco | 591,457 | 0 | 0 | 0 | For |
| Equitable | 331,345 | 0 | 0 | 165,041 | Mixed |
| Nationwide | 47,412 | 0 | 0 | 318,050 | Mixed |
| JPMorgan | 306,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 250,000 | Withhold |
| Columbia Threadneedle | 244,527 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 237,500 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 172,026 | Withhold |
| John Hancock | 125,876 | 0 | 0 | 40,876 | Mixed |
| GuideStone | 0 | 0 | 0 | 166,200 | Withhold |
| ProShares | 0 | 0 | 0 | 154,377 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 140,772 | Withhold |
| Brighthouse | 81,804 | 0 | 0 | 50,340 | Mixed |
| Dimensional | 0 | 0 | 0 | 113,711 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 113,627 | Withhold |
| Lincoln Financial | 93,800 | 0 | 0 | 17,215 | Mixed |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
97% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000 shares.
Allogene Therapeutics, Inc.’s own tally for this item (“4. Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares”): 221,767,995 for, 6,535,254 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares The Company's stockholders approved an amendment (the "Amendment") to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares o…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 64,731,884 for, 62,538 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,783,658 | 23,690 | 0 | 0 | For |
| Fidelity | 12,491,517 | 0 | 0 | 0 | For |
| BlackRock | 8,024,301 | 0 | 0 | 0 | For |
| State Street | 5,366,376 | 6,921 | 0 | 0 | For |
| T. Rowe Price | 3,707,029 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,375,270 | 0 | 0 | 0 | For |
| TIAA | 2,421,840 | 0 | 0 | 0 | For |
| Charles Schwab | 1,871,494 | 0 | 0 | 0 | For |
| Invesco | 591,457 | 0 | 0 | 0 | For |
| Equitable | 496,386 | 0 | 0 | 0 | For |
| Nationwide | 365,462 | 0 | 0 | 0 | For |
| JPMorgan | 306,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 250,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 244,527 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 237,500 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 172,026 | 0 | 0 | 0 | For |
| John Hancock | 166,752 | 0 | 0 | 0 | For |
| GuideStone | 166,200 | 0 | 0 | 0 | For |
| ProShares | 154,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 146,779 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,772 | 0 | 0 | 0 | For |
| Brighthouse | 132,144 | 0 | 0 | 0 | For |
| Dimensional | 113,711 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 113,627 | 0 | 0 | 0 | For |
| Lincoln Financial | 111,015 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 90.8% for (June 18, 2025 meeting) ▲ 3.9 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.
Allogene Therapeutics, Inc.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 213,098,167 for, 11,951,256 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,807,296 | 38 | 12 | 0 | For |
| Fidelity | 12,491,517 | 0 | 0 | 0 | For |
| BlackRock | 8,024,301 | 0 | 0 | 0 | For |
| State Street | 5,371,312 | 1,985 | 0 | 0 | For |
| T. Rowe Price | 3,707,029 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,375,270 | 0 | 0 | 0 | For |
| TIAA | 2,421,840 | 0 | 0 | 0 | For |
| Charles Schwab | 1,871,494 | 0 | 0 | 0 | For |
| Invesco | 0 | 591,457 | 0 | 0 | Against |
| Equitable | 496,386 | 0 | 0 | 0 | For |
| Nationwide | 365,462 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 306,515 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 250,000 | 0 | 0 | Against |
| Columbia Threadneedle | 244,527 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 237,500 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 172,026 | 0 | 0 | 0 | For |
| John Hancock | 166,752 | 0 | 0 | 0 | For |
| GuideStone | 166,200 | 0 | 0 | 0 | For |
| ProShares | 154,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 146,779 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,772 | 0 | 0 | 0 | For |
| Brighthouse | 50,340 | 81,804 | 0 | 0 | Mixed |
| Dimensional | 113,711 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 113,627 | 0 | 0 | 0 | For |
| Lincoln Financial | 111,015 | 0 | 0 | 0 | For |
Fund voting reports, all 51 managers: 63,442,227 for, 1,320,255 against, 31,939 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PFIZER INC | 22,032,040 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 18,796,668 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 12,721,798 | 0 | 0 | 0 | For |
| BlackRock | 10,146,623 | 107,889 | 0 | 0 | For |
| Fidelity | 9,488,610 | 0 | 0 | 0 | For |
| Citadel | 8,215,662 | 0 | 0 | 0 | For |
| State Street | 7,941,687 | 4,344 | 0 | 0 | For |
| T. Rowe Price | 5,117,721 | 0 | 0 | 0 | For |
| Aberdeen | 3,898,614 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,818,375 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 2,997,318 | 0 | 0 | Against |
| Wildcat Capital Management, LLC | 0 | 0 | 2,920,787 | 0 | Abstain |
| DE Shaw | 2,800,075 | 0 | 0 | 0 | For |
| Nuveen | 2,477,660 | 0 | 0 | 0 | For |
| AQR | 2,169,457 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 2,000,000 | 0 | 0 | 0 | For |
| Charles Schwab | 1,872,032 | 0 | 0 | 0 | For |
| Vanguard | 1,816,394 | 0 | 0 | 0 | For |
| Two Sigma | 1,554,353 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,496,992 | 0 | 0 | 0 | For |
| Ghisallo Capital Management LLC | 911,894 | 0 | 0 | 0 | For |
| Holocene Advisors, LP | 843,864 | 0 | 0 | 0 | For |
| Northern Trust | 799,033 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 798,899 | 0 | 0 | 0 | For |
| TPG GP A, LLC | 675,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 147 managers: 129,709,789 for, 4,668,565 against, 2,923,431 abstained, 500 not voted, 39,947 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 12 | 0 | Abstain |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| PRIMECAP Odyssey Funds | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Nationwide | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 0 | -- |
| Columbia Threadneedle | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| ETFis Series Trust I | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| GuideStone | 0 | 0 | 0 | 0 | -- |
| ProShares | 0 | 0 | 0 | 0 | -- |
| Delaware/Macquarie | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 132,144 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 51 managers: 132,144 for, 31,939 abstained, 64,404,333 1 year, 225,419 3 year, 588 unknown. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PFIZER INC | 0 | 0 | 0 | 0 | -- |
| Frazier Life Sciences Management, L.P. | 18,796,668 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Candriam S.C.A. | 0 | 0 | 0 | 0 | -- |
| Wildcat Capital Management, LLC | 0 | 0 | 2,920,787 | 0 | Abstain |
| DE Shaw | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| AQR | 0 | 0 | 0 | 0 | -- |
| DAFNA Capital Management LLC | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| Holocene Advisors, LP | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| BBR PARTNERS, LLC | 0 | 0 | 0 | 0 | -- |
| TPG GP A, LLC | 0 | 0 | 0 | 0 | -- |
| RTW INVESTMENTS, LP | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 140 managers: 18,837,403 for, 2,974,931 abstained, 500 not voted, 113,818,701 1 year, 284,578 3 year. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Approved · of votes cast
Prior year: 99.8% for (June 18, 2025 meeting) unchanged
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.
Allogene Therapeutics, Inc.’s own tally for this item (“5. Ratification of the Selection of Independent Registered Public Accounting Firm”): 282,022,884 for, 503,156 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 64,762,279 for, 216 against, 31,927 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,807,345 | 1 | 0 | 0 | For |
| Fidelity | 12,491,517 | 0 | 0 | 0 | For |
| BlackRock | 8,024,301 | 0 | 0 | 0 | For |
| State Street | 5,373,082 | 215 | 0 | 0 | For |
| T. Rowe Price | 3,707,029 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,375,270 | 0 | 0 | 0 | For |
| TIAA | 2,421,840 | 0 | 0 | 0 | For |
| Charles Schwab | 1,871,494 | 0 | 0 | 0 | For |
| Invesco | 591,457 | 0 | 0 | 0 | For |
| Equitable | 496,386 | 0 | 0 | 0 | For |
| Nationwide | 365,462 | 0 | 0 | 0 | For |
| JPMorgan | 306,515 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 250,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 244,527 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 237,500 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 172,026 | 0 | 0 | 0 | For |
| John Hancock | 166,752 | 0 | 0 | 0 | For |
| GuideStone | 166,200 | 0 | 0 | 0 | For |
| ProShares | 154,377 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 146,779 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 140,772 | 0 | 0 | 0 | For |
| Brighthouse | 132,144 | 0 | 0 | 0 | For |
| Dimensional | 113,711 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 113,627 | 0 | 0 | 0 | For |
| Lincoln Financial | 111,015 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 244,816,413 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.32% |
| 2 | Fidelity | 5.10% |
| 3 | BlackRock | 3.28% |
| 4 | State Street | 2.19% |
| 5 | T. Rowe Price | 1.51% |
| 6 | PRIMECAP Odyssey Funds | 1.38% |
| 7 | TIAA | 0.99% |
| 8 | Charles Schwab | 0.76% |
| 9 | Invesco | 0.24% |
| 10 | Equitable | 0.20% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PFIZER INC | 9.00% |
| 2 | Frazier Life Sciences Management, L.P. | 7.68% |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 5.20% |
| 4 | BlackRock | 4.19% |
| 5 | Fidelity | 3.88% |
| 6 | Citadel | 3.36% |
| 7 | State Street | 3.25% |
| 8 | T. Rowe Price | 2.09% |
| 9 | Aberdeen | 1.59% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.56% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Pfizer Inc. | 22,032,040 | 9.00% | Schedule 13D, filed February 13, 2026 |
| Frazier Life Sciences Public Fund, L.P. | 19,445,046 | 7.94% | Schedule 13G, filed August 14, 2026 |
| BlackRock | 19,091,095 | 7.80% | Form 13F, quarter ended March 31, 2026 |
| TPG GP A, LLC | 18,716,306 | 7.65% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| Arie Belldegrun, M.D. | 13,610,578 | 5.56% | Schedule 13G, filed August 7, 2026 |
| Citadel Multi-Strategy Equities Master Fund Ltd. | 13,346,151 | 5.45% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| David Chang, M.D., Ph.D. | 12,297,354 | 5.02% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| David D. Chang, M.D., Ph.D. | 12,297,354 | 5.02% | Schedule 13G, filed May 13, 2026 |
| Vanguard Group | 9,251,609 | 3.78% | Form 13F, quarter ended March 31, 2026 |
| State Street | 8,660,306 | 3.54% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 244,816,413 shares outstanding, as reported by Allogene Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Allogene Therapeutics, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 181 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,531 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Allogene Therapeutics, Inc.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Allogene Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 22, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Allogene Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Allogene Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Allogene Therapeutics (ALLO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/allogene-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.